UNSPSC 51281813: Aclarubicin hydrochloride

This classification denotes an aclacinomycin antibiotic with the molecular formula C42H53NO15.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501948RI66, chemically known as 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, methyl ester, hydrochloride, (1r-(1alpha,2beta,4beta))- but more generally known as aclarubicin hydrochloride, which bears US NIH Compound Identifier 153751.

UNSPSC 51281813 Aclarubicin hydrochloride is a Commodity code that shows minimal alignment with recent state and local procurement activity. The code nominally describes a specific chemotherapy agent, yet the recent opportunities tagged to it span naloxone procurement, pharmacy benefit program direct-to-manufacturer contracting, general medical and first aid supplies for fire rescue operations, and multi-state generic pharmaceutical cooperative purchasing—none of which involve aclarubicin or oncology pharmaceuticals specifically. The mismatch suggests either miscoding in the posting systems or that state and local buyers are using this code to flag pharmaceutical acquisitions more broadly rather than this narrow therapeutic category.

The recent opportunities do reveal substantial state and local purchasing activity in pharmaceutical and medical supply categories, though not under this code's nominal scope. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota MMCAP serving member states including Oregon). Geographic spread spans Florida, Texas, and the Upper Midwest with multi-state reach. Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023); the City of Tampa's IFB for medical and first aid supplies for its Fire Department Rescue Division with an estimated contract value of $700,000.00 and SLBE set-aside, due March 13, 2026; Texas HHS's RFI on direct-to-manufacturer pharmacy programs, with responses due April 3, 2026; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across participating state agencies, with proposals due March 26, 2026. The code shows little relevant recent activity and does not represent a reliable signal for aclarubicin or specialty oncology pharmaceutical procurement at the state and local level.